Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 312.00
Bid: 311.00
Ask: 313.00
Change: -3.00 (-0.95%)
Spread: 2.00 (0.643%)
Open: 320.00
High: 320.00
Low: 306.50
Prev. Close: 315.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Changes

11 Mar 2024 07:00

RNS Number : 2473G
Oxford Biomedica PLC
11 March 2024
 

 

 

Board changes following transformation to pure-play CDMO business model

Oxford, UK - 11 March 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "OXB" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that CDMO expert, Peter Soelkner, will join the Board as a Non-Executive Director, effective from 15 March 2024. Concurrently, as part of Oxford Biomedica's transformation into a pure-play CDMO, the Company announces that Catherine Moukheibir and Dr. Michael Hayden have informed the Board that they do not intend to stand for re-election at the upcoming Annual General Meeting in June 2024. Dr. Michael Hayden will continue to be an adviser to the Science and Technology Advisory Committee.

 

Peter Soelkner has more than 30 years' experience in the global pharmaceutical services industry with significant CDMO expertise. He is currently Managing Director of Vetter Pharma, a global Aseptic Filling and Packaging CDMO, where over the past 15 years he has helped grow revenues from $200 million to more than $1 billion. Prior to Vetter, Mr. Soelkner held various senior positions at Sartorius including Vice President of the Americas region where he expanded the global footprint of the business across the US and multiple sectors. He has an MBA from Columbia Business School, New York and Masters in Chemical Engineering from TU Dortmund University, Germany.

 

Dr. Roch Doliveux, Non-Executive Chairman of Oxford Biomedica, commented: "Alongside OXB's transformation to become a pure-play viral vector CDMO, the Board of Directors has reviewed its breadth of skills and taken the decision to streamline the Board whilst bolstering its CDMO expertise. In light of this, we are delighted to welcome Peter Soelkner given his impressive track record in significantly growing Vetter, a leading global CDMO from $200m to more than $1bn in revenues. In parallel, Catherine Moukheibir and Dr. Michael Hayden, who have played a defining role in shaping OXB's new strategy, both volunteered not to stand for re-election at the next AGM given that their strengths lie more in therapeutics rather than CDMO. I would like to personally thank Catherine and Michael for their impeccable service, loyalty and valuable insights."

 

Peter Soelkner commented: "I am pleased to be joining this innovative, client-centric, global business at such an exciting juncture in the Company's journey. In my view Oxford Biomedica is extremely well-positioned as a pure-play CDMO and I am excited to apply my skillset and experience to help deliver the strategy to clients, enabling them to deliver life-changing therapies to patients."

 

Relevant disclosures

 

There are no disclosures required to be made in accordance with LR 9.6.13R.

 

-Ends-

 

Enquiries:

 

Oxford Biomedica plc:

 

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 1865 509 737 / E: ir@oxb.com

 

ICR Consilium:

 

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy contract development and manufacturing organisation (CDMO) with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenoviral vectors, and other viral vector types. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFLFVTVRIILIS
Date   Source Headline
17th Jan 20144:35 pmRNSPrice Monitoring Extension
10th Jan 20147:00 amRNSPublication of ProSavin Phase I/II Study
9th Jan 201412:19 pmRNSOxford BioMedica to Present at Biotech Showcase
6th Jan 201410:28 amRNSOxford Biomedica PLC - General Meeting
18th Dec 20137:00 amRNSOXB option agreement with GSK
11th Dec 20137:00 amRNSCIRCULAR & GENERAL MEETING NOTIFICATION
22nd Nov 201312:38 pmRNSDirector/PDMR Shareholding
19th Nov 20137:00 amRNS£5 million Loan Facility from Lead Shareholder
19th Nov 20137:00 amRNSInterim Management Statement
17th Oct 20137:00 amRNSAgreement to Resume Clinical Trials
19th Sep 20137:00 amRNSDirector/PDMR Shareholding
17th Sep 20131:06 pmRNSBlock Listing Return
12th Sep 201311:18 amRNSOxford BioMedica plc Director's Share Purchase
11th Sep 20131:01 pmRNSOxford BioMedica Wins Significant Funding
6th Sep 20134:40 pmRNSSecond Price Monitoring Extn
6th Sep 20134:35 pmRNSPrice Monitoring Extension
29th Aug 20134:08 pmRNSTR1 Form
29th Aug 20137:00 amRNSInterim Results 2013
28th Aug 20137:00 amRNSUS$1 million Milestone Payment from Pfizer
14th Aug 20131:00 pmRNSAnnounced as Funding Competition Winner
29th Jul 20137:00 amRNSPublication of TroVax Phase II Analyses
23rd Jul 20137:00 amRNSNotice of Interim Results
16th Jul 201311:20 amRNSDirector/PDMR Shareholding
1st Jul 20137:00 amRNSUpdate on Glaucoma-GT
28th Jun 20137:00 amRNSTotal Voting Rights
20th Jun 201311:15 amRNSDirector/PDMR Shareholding
19th Jun 201311:00 amRNSTR-1: Notification of Major Interest in Shares
12th Jun 20137:00 amRNSDirectors' Interests in Share Options
10th Jun 201312:59 pmRNSDirector/PDMR Shareholding
10th Jun 201312:59 pmRNSTR-1: Notification of Major Interest in Shares
10th Jun 20137:00 amRNSDirector's Share Purchase
6th Jun 201311:45 amRNSResult of AGM
6th Jun 20137:00 amRNSChange of Adviser and Broker
6th Jun 20137:00 amRNSManagement and Board change
5th Jun 201310:43 amRNSTR-1: Notification of Major Interest in Shares
3rd Jun 20137:00 amRNSClinical Trial Update
24th May 201310:00 amRNSBLOCK LISTING RETURN
16th May 20137:00 amRNSInterim Management Statement
9th May 20139:00 amRNSUpdate from ARVO 2013
3rd May 20132:00 pmRNSHolding(s) in Company
3rd May 20132:00 pmRNSDirector/PDMR Shareholding
1st May 20137:03 amRNSCollaboration with Novartis
17th Apr 20131:00 pmRNS2012 ANNUAL REPORT & ACCOUNTS & AGM NOTIFICATION
7th Mar 20137:00 amRNSInitiation of PII Collaborative Study for TroVax
27th Feb 20137:00 amRNSPreliminary Results
25th Jan 20134:40 pmRNSSecond Price Monitoring Extn
25th Jan 20134:35 pmRNSPrice Monitoring Extension
23rd Jan 20137:00 amRNSNotice of Preliminary Results
29th Nov 20127:00 amRNSExercise of Option by ImaginAb
28th Nov 20127:00 amRNSBlock Listing Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.